The Form 4 filing, an SEC report of an insider's stock trades, lists Saggar Rajeev as chief medical officer. The sale took place on October 12, 2026. The report was filed on October 13, one day later.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-12 |
| Date of Latest Transaction | 2026-10-12 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 9,218 |
| Price | $28.48 |
| Total Transaction Value | $262,528.64 |
| Insider | |
| Ticker Symbol | LQDA |
| Company | Liquidia Corp |
| Insider Name | Saggar Rajeev |
| Insider Title | Chief Medical Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 126,368 |
| Position Size Change | 6.80% |
| Filing | |
| Filing Date | 2026-10-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of Liquidia Corp (LQDA) shares, reported with transaction code S. The record lists one sale transaction.
What was the average price of the transaction?
The average sale price was $28.48 per share.
How did this transaction affect the insider's holdings?
Saggar Rajeev sold 9,218 shares and reported owning 126,368 shares afterward. The shares sold were 6.80% of the reported shares owned before the sale.
What's the total transaction value?
The total reported value was $262,528.64 for the single sale transaction.
Are there any special circumstances around this transaction?
The transaction information notes a Rule 10b5-1 plan reference and a possible link to tax payments or stock option costs. A Rule 10b5-1 plan sets trading instructions in advance. A stock option gives someone the right to buy shares at a set price.
No footnote text was provided. It therefore remains unclear whether a plan covered this sale or which costs, if any, the sale covered. These details do not establish that taxes were the sale's only purpose.
For research purposes only; not investment advice.